JP2015521050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521050A5 JP2015521050A5 JP2015515598A JP2015515598A JP2015521050A5 JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5 JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- subject
- expression level
- copy number
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039189 Transcription factor Maf Human genes 0.000 claims 39
- 230000014509 gene expression Effects 0.000 claims 26
- 238000000034 method Methods 0.000 claims 20
- 206010027476 Metastases Diseases 0.000 claims 16
- 230000009401 metastasis Effects 0.000 claims 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 15
- 201000005202 lung cancer Diseases 0.000 claims 15
- 208000020816 lung neoplasm Diseases 0.000 claims 15
- 239000000523 sample Substances 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 13
- 102000014128 RANK Ligand Human genes 0.000 claims 12
- 108010025832 RANK Ligand Proteins 0.000 claims 12
- 210000000988 bone and bone Anatomy 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229940122361 Bisphosphonate Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000004663 bisphosphonates Chemical class 0.000 claims 6
- 230000015556 catabolic process Effects 0.000 claims 6
- 238000006731 degradation reaction Methods 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 102000055006 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- 102000004171 Cathepsin K Human genes 0.000 claims 3
- 108090000625 Cathepsin K Proteins 0.000 claims 3
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 238000010804 cDNA synthesis Methods 0.000 claims 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 3
- 229960004015 calcitonin Drugs 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 229960001251 denosumab Drugs 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 229940079488 strontium ranelate Drugs 0.000 claims 3
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- -1 EGFR inhibitors Chemical compound 0.000 claims 2
- 101001068638 Homo sapiens Basic salivary proline-rich protein 3 Proteins 0.000 claims 2
- 101000879840 Homo sapiens Serglycin Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007850 in situ PCR Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000011337 individualized treatment Methods 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656372P | 2012-06-06 | 2012-06-06 | |
| US61/656,372 | 2012-06-06 | ||
| PCT/IB2013/001859 WO2013182912A2 (en) | 2012-06-06 | 2013-06-06 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521050A JP2015521050A (ja) | 2015-07-27 |
| JP2015521050A5 true JP2015521050A5 (cg-RX-API-DMAC7.html) | 2016-08-04 |
| JP6386450B2 JP6386450B2 (ja) | 2018-09-05 |
Family
ID=49237517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515598A Active JP6386450B2 (ja) | 2012-06-06 | 2013-06-06 | 肺がん転移の診断、予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10006091B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3467124A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6386450B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102226219B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104603288B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013273242B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014030750A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2875918A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2859120T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2705237T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX368513B (cg-RX-API-DMAC7.html) |
| TR (1) | TR201819859T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013182912A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| WO2014184679A2 (en) * | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| EP2971113B1 (en) * | 2013-03-15 | 2020-08-12 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| WO2015187612A1 (en) * | 2014-06-02 | 2015-12-10 | Valley Health System | Method and systems for lung cancer diagnosis |
| CN104398506A (zh) * | 2014-12-09 | 2015-03-11 | 厦门大学 | 雷奈酸锶在制备预防和治疗腺癌药物中的新用途 |
| CA2967224C (en) * | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| JP2018512401A (ja) | 2015-03-12 | 2018-05-17 | モイライ マトリックス インコーポレイテッド | Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| CN105154542B (zh) * | 2015-09-01 | 2018-04-17 | 杭州源清生物科技有限公司 | 一组用于肺癌分子分型的基因及其应用 |
| EP3420000A1 (en) * | 2016-02-25 | 2019-01-02 | Cell Medica Switzerland AG | Modified cells for immunotherapy |
| WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
| DK3901283T3 (da) | 2016-05-25 | 2025-09-15 | Inbiomotion Sl | Terapeutisk behandling af brystkræft baseret på c-maf-status |
| CN106055921A (zh) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | 基于基因表达和药物靶标的药物活性预测与筛选方法 |
| CN106119405B (zh) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用 |
| CN107058480B (zh) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院（河北省肿瘤医院） | 用于诊断肺腺癌的长链非编码rna标志物 |
| CN106815486B (zh) * | 2017-01-22 | 2021-06-04 | 华中农业大学 | 一种个性化用药的系统药理学方法 |
| CN107058499B (zh) * | 2017-01-25 | 2020-03-13 | 河北医科大学第四医院（河北省肿瘤医院） | 一种用于肺腺癌诊治的分子标志物 |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
| WO2019152788A1 (en) | 2018-02-02 | 2019-08-08 | Morgan And Mendel Genomics, Inc. | Robust genomic predictor of breast and lung cancer metastasis |
| KR102218199B1 (ko) | 2019-01-31 | 2021-02-22 | 중앙대학교 산학협력단 | 폐암 전이 예측용 바이오마커 조성물 |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| CN110093422A (zh) * | 2019-05-24 | 2019-08-06 | 中国人民解放军西部战区总医院 | Linc02159在肺腺癌诊疗中的应用 |
| KR102260915B1 (ko) * | 2020-02-19 | 2021-06-04 | 한국원자력의학원 | 폐암의 방사선 치료 예후 예측을 위한 생체 표지자 |
| CN119143798B (zh) * | 2024-08-01 | 2025-09-30 | 河北医科大学 | 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用 |
| CN119876392B (zh) * | 2025-01-06 | 2025-08-12 | 上海市第六人民医院 | 一种用于辅助诊断肺腺癌骨转移的生物标志物 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004920A1 (en) | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6017729A (en) | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EP1178958B1 (en) | 1999-03-15 | 2004-02-18 | Axys Pharmaceuticals, Inc. | N-cyanomethyl amides as protease inhibitors |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| EP1248612B1 (en) | 2000-01-06 | 2008-02-27 | Merck Frosst Canada Ltd. | Novel compounds and compositions as protease inhibitors |
| US7214781B2 (en) | 2000-06-21 | 2007-05-08 | Hitachi Chemical Research Center, Inc. | Gene markers for lung cancer |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| NO345566B1 (no) | 2001-06-26 | 2021-04-19 | Amgen Inc | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050060771A1 (en) | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| CA2558808A1 (en) * | 2004-03-05 | 2005-09-22 | Rosetta Inpharmatics Llc | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| JP5457673B2 (ja) | 2005-09-20 | 2014-04-02 | ベリデックス・リミテッド・ライアビリティ・カンパニー | ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用 |
| EP1931994A2 (en) * | 2005-09-26 | 2008-06-18 | Novartis AG | Molecular markers associated with bone metastasis |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| JP2010527914A (ja) * | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| EP2152747B1 (en) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2009049410A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| CA2726537A1 (en) | 2008-06-06 | 2009-12-10 | University Health Network | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
| WO2010000796A1 (en) * | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| US10047398B2 (en) * | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2671076A4 (en) | 2011-02-04 | 2016-11-16 | Bioarray Genetics Inc | METHODS OF USING GENE EXPRESSION SIGNATURES FOR SELECTING A TREATMENT METHOD, PREDICTING PROGNOSIS, SURVIVAL, AND / OR PREDICTING A RESPONSE TO TREATMENT |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| EP2971113B1 (en) * | 2013-03-15 | 2020-08-12 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| KR20160061424A (ko) | 2013-10-09 | 2016-05-31 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 |
| SMT202400270T1 (it) | 2014-06-17 | 2024-07-09 | Asherman Therapy S L | Terapia con cellule staminali in patologie endometriali |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3901283T3 (da) | 2016-05-25 | 2025-09-15 | Inbiomotion Sl | Terapeutisk behandling af brystkræft baseret på c-maf-status |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
-
2013
- 2013-06-06 BR BR112014030750A patent/BR112014030750A2/pt not_active Application Discontinuation
- 2013-06-06 EP EP18206025.1A patent/EP3467124A1/en not_active Withdrawn
- 2013-06-06 US US14/405,724 patent/US10006091B2/en active Active
- 2013-06-06 CN CN201380037529.4A patent/CN104603288B/zh active Active
- 2013-06-06 MX MX2014014802A patent/MX368513B/es active IP Right Grant
- 2013-06-06 CA CA2875918A patent/CA2875918A1/en not_active Abandoned
- 2013-06-06 ES ES13766663T patent/ES2705237T3/es active Active
- 2013-06-06 JP JP2015515598A patent/JP6386450B2/ja active Active
- 2013-06-06 WO PCT/IB2013/001859 patent/WO2013182912A2/en not_active Ceased
- 2013-06-06 TR TR2018/19859T patent/TR201819859T4/tr unknown
- 2013-06-06 EP EP13766663.2A patent/EP2859120B1/en active Active
- 2013-06-06 AU AU2013273242A patent/AU2013273242B2/en active Active
- 2013-06-06 DK DK13766663.2T patent/DK2859120T3/en active
- 2013-06-06 KR KR1020147035982A patent/KR102226219B1/ko active Active
-
2018
- 2018-05-21 US US15/984,629 patent/US11352673B2/en active Active
-
2019
- 2019-06-18 AU AU2019204269A patent/AU2019204269A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521050A5 (cg-RX-API-DMAC7.html) | ||
| Meng et al. | Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients | |
| JP2016516403A5 (cg-RX-API-DMAC7.html) | ||
| Thomas et al. | Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease | |
| JP2015520606A5 (cg-RX-API-DMAC7.html) | ||
| Pichler et al. | miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor | |
| Song et al. | Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family | |
| Shames et al. | High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck | |
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| Hung et al. | Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma | |
| JP2013541339A5 (cg-RX-API-DMAC7.html) | ||
| JP2018078911A5 (cg-RX-API-DMAC7.html) | ||
| Shen et al. | microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation | |
| Kanda et al. | B-cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma | |
| JP2019523641A5 (cg-RX-API-DMAC7.html) | ||
| Lin et al. | Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway | |
| JP2012522756A5 (cg-RX-API-DMAC7.html) | ||
| JP6931926B2 (ja) | 遺伝子発現プロファイル及び乳癌におけるその使用 | |
| Davidson et al. | Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions | |
| JP2008536480A5 (cg-RX-API-DMAC7.html) | ||
| EP3215635A1 (en) | Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis | |
| JP2014533960A5 (cg-RX-API-DMAC7.html) | ||
| Pan et al. | miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma |